Single-arm phase ii study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high-grade gliomas: Final report

Strahlentherapie und Onkologie

Volumn 186, Issue 10, 2010, Pages 558-564

  Balducci, Mario ^a   Apicella, Giuseppina ^a,b   Manfrida, Stefania ^a   Mangiola, Annunziato ^a   Fiorentino, Alba ^a   Azario, Luigi ^a   D'Agostino, Giuseppe Roberto ^a   Frascino, Vincenzo ^a   Dinapoli, Nicola ^a   Mantini, Giovanna ^a   Albanese, Alessio ^a   De Bonis, Pasquale ^a   Chiesa, Silvia ^a   Valentini, Vincenzo ^a   Anile, Carmelo ^a   Cellini, Numa ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b University Hospital Maggiore della Carita   (Italy)

Author keywords

Boost; Malignant glioma; Stereotactic radiotherapy; Temozolomide

Indexed keywords

TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BRAIN TOXICITY; CANCER CONTROL; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFUSION; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FRACTIONATED STEREOTACTIC CONFORMAL RADIOTHERAPY; GLIOBLASTOMA; GLIOMA; HEADACHE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION NECROSIS; SEIZURE; STEREOTACTIC BODY RADIATION THERAPY; THREE DIMENSIONAL IMAGING; TREATMENT RESPONSE;

ACTUARIAL ANALYSIS; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; COMBINED MODALITY THERAPY; DACARBAZINE; FEMALE; FOLLOW-UP STUDIES; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOSURGERY; RADIOTHERAPY, CONFORMAL; SURVIVAL RATE;

EID: 78650174731     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-010-2101-x     Document Type: Article

References (37)

1. Aydn H, Sillenberg I, von Lieven H, et al. Patterns of failure following CT-based 3-D irradiation for malignant glioma. Strahlenther Onkol 2001;177:424-31. (Pubitemid 32756556)
2. Balducci M, DAgostino GR, Manfrida S, et al. Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: long-term analysis of a phase II study. J Neurooncol 2010;97:95-100.
3. Baumert BG, Lutterbach J, Bernays R, et al. Fractionated stereotactic radiotherapy boost after post-operative radiotherapy in patients with high-grade gliomas. Radiother Oncol 2003;67:183-90. (Pubitemid 36700461)
4. Cardinale R, Won M, Choucair A, et al. A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol Biol Phys 2006;65:1422-8. (Pubitemid 44425201)
5. Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 2002;20:1635-42. (Pubitemid 34260545)
6. Cho KH, Hall WA, Lo SS, et al. Stereotactic radiosurgery versus fractionated stereotactic radiotherapy boost for patients with glioblastoma multiforme. Technol Cancer Res Treat 2004;3:41-9. (Pubitemid 38250467)
7. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-229.
8. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-6.
9. Curran WJ Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85:704-10. (Pubitemid 23133591)
10. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic radiation. Int J Radiat Oncol Biol Phys 1991;21:109-22.
11. Erlich SS, Davis RL. Spinal subarachnoid metastasis from primary intracranial glioblastoma multiforme. Cancer 1978;42:2854-64. (Pubitemid 9107566)
12. Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas. A beneficial treatment option after high-dose radiotherapy? Strahlenther Onkol 2009;185:235-40.
13. Glas M, Happold C, Rieger W, et al. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol 2009;27:1257-61.
14. Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlenther Onkol 2009;185:113-9.
15. Iliades G, Selviaridis P, Kalogera-Fountzila A, et al. The importance of tumor volume in the prognosis of patients with glioblastoma. Comparison of computerized volumetry and geometric models. Strahlenther Onkol 2009;185:743-50.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457.
17. Lai A, Filka E, McGibbon B, et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 2008;71:1372-80.
18. Lamborn KR, Chang SM, Prados MD. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol 2004;6:227-35. (Pubitemid 39136506)
19. Lee SW, Fraass BA, Marsh LH, et al. Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys 1999;43:79-88. (Pubitemid 29065835)
20. Macdonald DR, Cascino TL, Schold SC, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80. (Pubitemid 20195640)
21. Mangiola A, de Bonis P, Maira G, et al. Invasive tumor cells and prognosis in a selected population of patients with glioblastoma multiforme. Cancer 2008;113:841-6.
22. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;5:163-70.
23. Marks JE, Baglan RJ, Prassad SC, et al. Cerebral radionecrosis: incidence and risk in relation to dose, time, fractionation and volume. Int J Radiat Oncol Biol Phys 1981;7:243-52. (Pubitemid 11149307)
24. Mirinamoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 2006;24:2563-9. (Pubitemid 46630635)
25. Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not improve survival in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1998;40:1141-9. (Pubitemid 28152930)
26. Narayana A, Golfinos JG, Fischer I, et al. Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys 2008;72:383-9.
27. Nieder C, Andratschke N, Wiedenmann N, et al. Radiotherapy for high-grade gliomas. Does altered fractionation improve the outcome? Strahlenther Onkol 2004;180:401-7. (Pubitemid 39207378)
28. Nwokedi EC, DiBiase SJ, Jabbour S, et al. Gamma knife stereotactic radiosurgery for patients with glioblastoma multiforme. Neurosurgery 2002;50:41-6. (Pubitemid 41672553)
29. Park I, Tamai G, Lee MC, et al. Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings. Int J Radiat Oncol Biol Phys 2007;69:381-9. (Pubitemid 47380095)
30. Regine WF, Patchell RA, Strottmann JM, et al. Preliminary report of a phase I study of combined fractionated stereotactic radiosurgery and conventional external beam radiation therapy for unfavourable gliomas. Int J Radiat Oncol Biol Phys 2000;48:421-6.
31. Rickhey M, Koelbl O, Eilles C, Bogner L. A biologically adapted dose-escalation approach, demonstrated for 18F-FET-PET in brain tumors. Strahlenther Onkol 2008;184:536-42.
32. Sarkaria JN, Mehta MP, Loeffler JS, et al. Radiosurgery in the initial management of malignant gliomas: survival comparison with the RTOG recursive partitioning analysis. Int J Radiat Oncol Biol Phys 1995;32:931-41.
33. Shepherd SF, Laing RW, Cosgrove VP, et al. Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys 1997;37:393-8. (Pubitemid 27138724)
34. Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 2004;60:853-60. (Pubitemid 39311766)
35. Stupp R, Hegi ME, Gilbert MR, Chakravarti A. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 2007; 25:4127-36. (Pubitemid 47492957)
36. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96. (Pubitemid 40349501)
37. Walker MD, Strike T, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979;5:1725-31. (Pubitemid 10187518)